Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Sven G Meuth, Antonios Bayas, Boris Kallmann, Ralf Linker, Peter Rieckmann, Mike P Wattjes, Mathias Mäurer & Christoph Kleinschnitz. (2022) Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opinion on Pharmacotherapy 23:13, pages 1503-1510.
Read now
Read now
Trygve Holmøy, Øivind Torkildsen & Kjell-Morten Myhr. (2017) An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opinion on Pharmacotherapy 18:15, pages 1627-1635.
Read now
Read now
Emanuele D’Amico, Tjalf Ziemssen & Salvatore Cottone. (2017) Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion. Expert Opinion on Pharmacotherapy 18:15, pages 1553-1556.
Read now
Read now
Friedemann Paul. (2013) Cladribine in multiple sclerosis: pitfalls in a new treatment landscape. Expert Opinion on Pharmacotherapy 14:1, pages 1-3.
Read now
Read now
Articles from other publishers (18)
Robert Hermann, Peter Krajcsi, Markus Fluck, Annick Seithel-Keuth, Afrim Bytyqi, Andrew Galazka & Alain Munafo. (2021) Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions. Clinical Pharmacokinetics 61:2, pages 167-187.
Crossref
Crossref
Robert Hermann, Peter Krajcsi, Markus Fluck, Annick Seithel-Keuth, Afrim Bytyqi, Andrew Galazka & Alain Munafo. (2021) Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine. Clinical Pharmacokinetics 60:12, pages 1509-1535.
Crossref
Crossref
Augusto A Miravalle, Joshua Katz, Derrick Robertson, Brooke Hayward, Danielle E Harlow, Lori A Lebson, Jacob A Sloane, Ann D Bass & Edward J Fox. (2021) CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. Neurodegenerative Disease Management 11:2, pages 99-111.
Crossref
Crossref
Halina Bartosik-Psujek, Łukasz Kaczyński, Magdalena Górecka, Mirosław Rolka, Rafał Wójcik, Patrycja Zięba & Marcin Kaczor. (2021) Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis–A systematic review and network meta-analysis. Multiple Sclerosis and Related Disorders 49, pages 102769.
Crossref
Crossref
Johann Sellner & Paulus S. Rommer. (2020) Immunological consequences of “immune reconstitution therapy” in multiple sclerosis: A systematic review. Autoimmunity Reviews 19:4, pages 102492.
Crossref
Crossref
Robert Hermann, Jeffrey S. Litwin, Lena E. Friberg, Fernando Dangond & Alain Munafo. (2019) Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis. British Journal of Clinical Pharmacology 85:7, pages 1484-1494.
Crossref
Crossref
Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Andrew Galazka, Axel Nolting, Christine Hicking & Fernando Dangond. (2019) Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders 29, pages 168-174.
Crossref
Crossref
Robert Hermann, Mats O. Karlsson, Ana M. Novakovic, Nadia Terranova, Markus Fluck & Alain Munafo. (2018) The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis. Clinical Pharmacokinetics 58:3, pages 283-297.
Crossref
Crossref
Chaonan Ye, Kun Han, Jinxiu Lei, Kui Zeng, Su Zeng, Haixing Ju & Lushan Yu. (2018) Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state. British Journal of Pharmacology 175:22, pages 4209-4217.
Crossref
Crossref
A.M. Novakovic, A. Thorsted, E. Schindler, S. Jönsson, A. MunafoM.O. Karlsson. (2018) Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials. The Journal of Clinical Pharmacology 58:10, pages 1284-1294.
Crossref
Crossref
Zhifeng Mao, César Álvarez-Gonzalez, Stefania De Trane, Ozlem Yildiz, Christo Albor, Gabriel Doctor, Derek Soon, George Pepper, Benjamin P Turner, Monica Marta, Joela Mathews, Gavin Giovannoni, David Baker & Klaus Schmierer. (2018) Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:2, pages 205521731878376.
Crossref
Crossref
R. S. Nicholas, A. Nandoskar, M. Hutchinson & T. Friede. 2018. Progressive Multiple Sclerosis. Progressive Multiple Sclerosis
233
252
.
Mark S Freedman, Thomas P Leist, Giancarlo Comi, Bruce AC Cree, Patricia K Coyle, Hans-Peter Hartung, Patrick Vermersch, Doris Damian & Fernando Dangond. (2017) The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical 3:4, pages 205521731773280.
Crossref
Crossref
A. Nandoskar, J. Raffel, A. S. Scalfari, T. Friede & R. S. Nicholas. (2017) Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. Drugs 77:8, pages 885-910.
Crossref
Crossref
Karl B. Alstadhaug, Randi Fykse Halstensen & Francis Odeh. (2017) Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine. Journal of Clinical Virology 88, pages 17-20.
Crossref
Crossref
Melanie Korsen, Sara Bragado Alonso, Lizzy Peix, Barbara M. Bröker & Alexander Dressel. (2015) Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells. PLOS ONE 10:6, pages e0129182.
Crossref
Crossref
Regina Berkovich & Mark A. Agius. (2014) Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis. Therapeutic Advances in Neurological Disorders 7:2, pages 83-96.
Crossref
Crossref
Stefan H.P. Kraus, Felix Luessi, Bettina Trinschek, Steffen Lerch, Mario Hubo, Laura Poisa-Beiro, Magdalena Paterka, Helmut Jonuleit, Frauke Zipp & Valérie Jolivel. (2014) Cladribine exerts an immunomodulatory effect on human and murine dendritic cells. International Immunopharmacology 18:2, pages 347-357.
Crossref
Crossref